Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan.
Anticancer Res. 2011 Oct;31(10):3361-8.
While the benefit of passive immunotherapy is commonly accepted, active immunization may have advantages for the patient's quality of life. We identified a new epitope of Mab CH401 against Her-2/neu extracellular domain (N: 167-175), and evaluated the effect of active immunization of the 20mer peptide containing the epitope (CH401 peptide).
Epitope-mapping was performed using ELISA with Her-2/neu-related multiple antigen peptides (MAP). BALB/c mice were transplanted with Her-2/neu-expressing lymphoma cell line and immunized with the peptides. For monitoring the condition, ELISA and flow cytometry was performed.
CH401 peptide induced Her-2/neu-specific IgG antibody. Tumor growth in immunized mice was suppressed and tumor-infiltrating lymphocytes comprised more CD8(+) T-cells, which secreted larger amounts of interleukin-2 after the peptide re-stimulation.
The new Her-2/neu peptide contained epitopes for CD4(+) and CD8(+) T-cells, which contributes to the suppressive effect on Her-2/neu-expressing tumor cell growth.
虽然被动免疫疗法的益处已被普遍接受，但主动免疫可能对患者的生活质量具有优势。我们鉴定了针对 Her-2/neu 细胞外结构域的 Mab CH401 的一个新表位（N：167-175），并评估了包含该表位的 20 肽的主动免疫接种的效果（CH401 肽）。
使用与 Her-2/neu 相关的多种抗原肽（MAP）的 ELISA 进行表位作图。将 Her-2/neu 表达的淋巴瘤细胞系移植到 BALB/c 小鼠中，并使用这些肽进行免疫接种。为了监测情况，进行了 ELISA 和流式细胞术分析。
CH401 肽诱导了 Her-2/neu 特异性 IgG 抗体。免疫接种小鼠的肿瘤生长受到抑制，并且肿瘤浸润淋巴细胞中 CD8(+) T 细胞增多，在肽再刺激后分泌更多的白细胞介素 2。
新的 Her-2/neu 肽包含 CD4(+)和 CD8(+) T 细胞的表位，有助于抑制 Her-2/neu 表达的肿瘤细胞生长。
